Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.
Hepatitis C virus (HCV)-related liver diseases have contributed to increased morbidity and mortality in HIV-1-infected individuals in the era of effective antiretroviral therapy. HCV transmission patterns have changed among the HIV co-infected population during the last decade, with acute HCV infection emerging worldwide. HIV infection accelerates the progression of HCV-related liver diseases and consequently cirrhosis, liver failure, and hepatocellular carcinoma. However, the current standard treatment of HCV infection with pegylated interferon plus ribavirin results in only a limited viral response. Furthermore, cumbersome pill regimens, antiretroviral related hepatotoxicity, and drug interactions of HCV and HIV regimens complicate therapy strategies. Fortunately, in the near future, new direct-acting anti-HCV agents will widen therapeutic options for HCV/HIV co-infection. Liver transplantation is also gradually accepted as a therapeutic option for end stage liver disease of HCV/HIV co-infected patients.
Department of Public Health Sciences, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
Wen
W
Kang
Hsin-I
HI
Tong
Yongtao
Y
Sun
Yuanan
Y
Lu
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015897:Comorbidity; D019468:Disease Management; D018450:Disease Progression; D058625:End Stage Liver Disease / Q000601:surgery / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000821:virology; D015497:HIV-1 / Q000472:pathogenicity*; D016174:Hepacivirus / Q000472:pathogenicity*; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016031:Liver Transplantation; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a